Cargando…
Global burden of hematologic malignancies and evolution patterns over the past 30 years
Hematologic malignancies are among the most common cancers, and understanding their incidence and death is crucial for targeting prevention, clinical practice improvement, and research resources appropriately. Here, we investigated detailed information on hematological malignancies for the period 19...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188596/ https://www.ncbi.nlm.nih.gov/pubmed/37193689 http://dx.doi.org/10.1038/s41408-023-00853-3 |
_version_ | 1785042948329570304 |
---|---|
author | Zhang, Nan Wu, Jinxian Wang, Qian Liang, Yuxing Li, Xinqi Chen, Guopeng Ma, Linlu Liu, Xiaoyan Zhou, Fuling |
author_facet | Zhang, Nan Wu, Jinxian Wang, Qian Liang, Yuxing Li, Xinqi Chen, Guopeng Ma, Linlu Liu, Xiaoyan Zhou, Fuling |
author_sort | Zhang, Nan |
collection | PubMed |
description | Hematologic malignancies are among the most common cancers, and understanding their incidence and death is crucial for targeting prevention, clinical practice improvement, and research resources appropriately. Here, we investigated detailed information on hematological malignancies for the period 1990–2019 from the Global Burden of Disease study. The age-standardized incidence rate (ASIR), the age-standardized death rate (ASDR), and the corresponding estimated annual percentage changes (EAPC) were calculated to assess temporal trends in 204 countries and territories over the past 30 years. Globally, incident cases of hematologic malignancies have been increasing since 1990, reaching 1343.85 thousand in 2019, but the ASDR for all types of hematologic malignancies has been declining. The ASDR for leukemia, multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma were 4.26, 1.42, 3.19, and 0.34 per 100,000 population in 2019, respectively, with Hodgkin lymphoma showing the most significant decline. However, the trend varies by gender, age, region, and the country’s economic situation. The burden of hematologic malignancies is generally higher in men, and this gender gap decreases after peaking at a given age. The regions with the largest increasing trend in the ASIR of leukemia, multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma were Central Europe, Eastern Europe, East Asia, and Caribbean, respectively. In addition, the proportion of deaths attributed to high body-mass index continued to rise across regions, especially in regions with high socio-demographic indices (SDI). Meanwhile, the burden of leukemia from occupational exposure to benzene and formaldehyde was more widespread in areas with low SDI. Thus, hematologic malignancies remain the leading cause of the global tumor burden, with growing absolute numbers but sharp among several age-standardized measures over the past three decades. The results of the study will inform analysis of trends in the global burden of disease for specific hematologic malignancies and develop appropriate policies for these modifiable risks. [Image: see text] |
format | Online Article Text |
id | pubmed-10188596 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-101885962023-05-18 Global burden of hematologic malignancies and evolution patterns over the past 30 years Zhang, Nan Wu, Jinxian Wang, Qian Liang, Yuxing Li, Xinqi Chen, Guopeng Ma, Linlu Liu, Xiaoyan Zhou, Fuling Blood Cancer J Article Hematologic malignancies are among the most common cancers, and understanding their incidence and death is crucial for targeting prevention, clinical practice improvement, and research resources appropriately. Here, we investigated detailed information on hematological malignancies for the period 1990–2019 from the Global Burden of Disease study. The age-standardized incidence rate (ASIR), the age-standardized death rate (ASDR), and the corresponding estimated annual percentage changes (EAPC) were calculated to assess temporal trends in 204 countries and territories over the past 30 years. Globally, incident cases of hematologic malignancies have been increasing since 1990, reaching 1343.85 thousand in 2019, but the ASDR for all types of hematologic malignancies has been declining. The ASDR for leukemia, multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma were 4.26, 1.42, 3.19, and 0.34 per 100,000 population in 2019, respectively, with Hodgkin lymphoma showing the most significant decline. However, the trend varies by gender, age, region, and the country’s economic situation. The burden of hematologic malignancies is generally higher in men, and this gender gap decreases after peaking at a given age. The regions with the largest increasing trend in the ASIR of leukemia, multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma were Central Europe, Eastern Europe, East Asia, and Caribbean, respectively. In addition, the proportion of deaths attributed to high body-mass index continued to rise across regions, especially in regions with high socio-demographic indices (SDI). Meanwhile, the burden of leukemia from occupational exposure to benzene and formaldehyde was more widespread in areas with low SDI. Thus, hematologic malignancies remain the leading cause of the global tumor burden, with growing absolute numbers but sharp among several age-standardized measures over the past three decades. The results of the study will inform analysis of trends in the global burden of disease for specific hematologic malignancies and develop appropriate policies for these modifiable risks. [Image: see text] Nature Publishing Group UK 2023-05-17 /pmc/articles/PMC10188596/ /pubmed/37193689 http://dx.doi.org/10.1038/s41408-023-00853-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Zhang, Nan Wu, Jinxian Wang, Qian Liang, Yuxing Li, Xinqi Chen, Guopeng Ma, Linlu Liu, Xiaoyan Zhou, Fuling Global burden of hematologic malignancies and evolution patterns over the past 30 years |
title | Global burden of hematologic malignancies and evolution patterns over the past 30 years |
title_full | Global burden of hematologic malignancies and evolution patterns over the past 30 years |
title_fullStr | Global burden of hematologic malignancies and evolution patterns over the past 30 years |
title_full_unstemmed | Global burden of hematologic malignancies and evolution patterns over the past 30 years |
title_short | Global burden of hematologic malignancies and evolution patterns over the past 30 years |
title_sort | global burden of hematologic malignancies and evolution patterns over the past 30 years |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188596/ https://www.ncbi.nlm.nih.gov/pubmed/37193689 http://dx.doi.org/10.1038/s41408-023-00853-3 |
work_keys_str_mv | AT zhangnan globalburdenofhematologicmalignanciesandevolutionpatternsoverthepast30years AT wujinxian globalburdenofhematologicmalignanciesandevolutionpatternsoverthepast30years AT wangqian globalburdenofhematologicmalignanciesandevolutionpatternsoverthepast30years AT liangyuxing globalburdenofhematologicmalignanciesandevolutionpatternsoverthepast30years AT lixinqi globalburdenofhematologicmalignanciesandevolutionpatternsoverthepast30years AT chenguopeng globalburdenofhematologicmalignanciesandevolutionpatternsoverthepast30years AT malinlu globalburdenofhematologicmalignanciesandevolutionpatternsoverthepast30years AT liuxiaoyan globalburdenofhematologicmalignanciesandevolutionpatternsoverthepast30years AT zhoufuling globalburdenofhematologicmalignanciesandevolutionpatternsoverthepast30years |